Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case.
Vallacchi V, Vergani E, Cossa M, Gargiuli C, Busico A, Devecchi A, Dugo M, Bergamaschi L, De Cecco L, Cavalieri S, Valeri B, Tamborini E, Gallino G, Del Vecchio M, Santinami M, Sensi M, Rivoltini L, Di Guardo L, Rodolfo M. Vallacchi V, et al. Among authors: santinami m. J Immunother Cancer. 2024 Jan 4;12(1):e007612. doi: 10.1136/jitc-2023-007612. J Immunother Cancer. 2024. PMID: 38177075 Free PMC article.
Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.
Vallacchi V, Vergani E, Camisaschi C, Deho P, Cabras AD, Sensi M, De Cecco L, Bassani N, Ambrogi F, Carbone A, Crippa F, Vergani B, Frati P, Arienti F, Patuzzo R, Villa A, Biganzoli E, Canevari S, Santinami M, Castelli C, Rivoltini L, Rodolfo M. Vallacchi V, et al. Among authors: santinami m. Cancer Res. 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672. Cancer Res. 2014. PMID: 24395820
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Vergani E, et al. Among authors: santinami m. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599. Oncotarget. 2016. PMID: 26684239 Free PMC article.
microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.
Vallacchi V, Camisaschi C, Dugo M, Vergani E, Deho P, Gualeni A, Huber V, Gloghini A, Maurichi A, Santinami M, Sensi M, Castelli C, Rivoltini L, Rodolfo M. Vallacchi V, et al. Among authors: santinami m. Genes (Basel). 2016 Dec 14;7(12):124. doi: 10.3390/genes7120124. Genes (Basel). 2016. PMID: 27983661 Free PMC article.
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G, Mattavelli I, Vergani B, Lalli L, Tamborini E, Valeri B, Gargiuli C, Shahaj E, Ferrarini M, Ferrero E, Gomez Lira M, Huber V, Del Vecchio M, Sensi M, Leone BE, Santinami M, Rivoltini L, Rodolfo M, Vallacchi V. Vergani E, et al. Among authors: santinami m. Cell Commun Signal. 2020 Sep 23;18(1):156. doi: 10.1186/s12964-020-00601-1. Cell Commun Signal. 2020. PMID: 32967672 Free PMC article.
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.
Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Di Guardo L, et al. Among authors: santinami m. Oncologist. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21. Oncologist. 2021. PMID: 34355463 Free PMC article.
Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles.
Vergani E, Busico A, Dugo M, Devecchi A, Valeri B, Cossa M, Di Guardo L, De Cecco L, Feltrin E, Valle G, Deho P, Frigerio S, Lalli L, Gallino G, Del Vecchio M, Santinami M, Pruneri G, Tamborini E, Rivoltini L, Sensi M, Vallacchi V, Rodolfo M. Vergani E, et al. Among authors: santinami m. J Invest Dermatol. 2022 Nov;142(11):3030-3040.e5. doi: 10.1016/j.jid.2022.04.027. Epub 2022 May 26. J Invest Dermatol. 2022. PMID: 35643181 Free article.
Melanoma immunology: past, present and future.
Parmiani G, Castelli C, Santinami M, Rivoltini L. Parmiani G, et al. Among authors: santinami m. Curr Opin Oncol. 2007 Mar;19(2):121-7. doi: 10.1097/CCO.0b013e32801497d7. Curr Opin Oncol. 2007. PMID: 17272984 Review.
Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension.
Maurichi A, Barretta F, Patuzzo R, Miceli R, Gallino G, Mattavelli I, Barbieri C, Leva A, Angi M, Lanza FB, Spadola G, Cossa M, Nesa F, Cortinovis U, Sala L, Di Guardo L, Cimminiello C, Del Vecchio M, Valeri B, Santinami M. Maurichi A, et al. Among authors: santinami m. J Natl Compr Canc Netw. 2021 Jul 26;19(10):1165-1173. doi: 10.6004/jnccn.2020.7693. J Natl Compr Canc Netw. 2021. PMID: 34311443
171 results